{"transactions":[{"id":1842550,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-28T22:12:57.000Z","date":"2023-06-27","kind":"sale","planned":false,"acquired":false,"shares":937404,"price":0.5194,"value":486887.6376,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.4976 to $0.5985, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities of the Issuer are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":731458,"source":{"system":"sec-edgar","filing":"0000899243-23-016659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924323016659/doc4.xml","form_type":"4"}},{"id":1842549,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-06-28T22:12:57.000Z","date":"2023-06-26","kind":"sale","planned":false,"acquired":false,"shares":2746138,"price":0.6125,"value":1682009.525,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.50 to $0.7801, inclusive. The Reporting Person undertakes to provide to Avalo Therapeutics, Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote and footnote 3."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities of the Issuer are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1668862,"source":{"system":"sec-edgar","filing":"0000899243-23-016659","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924323016659/doc4.xml","form_type":"4"}},{"id":2024388,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2023-02-09T21:32:03.000Z","date":"2023-02-07","kind":"purchase","acquired":true,"shares":450000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"These shares are directly owned by Mr. Boyd in his personal capacity."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amount reflects the effect of the 1-for-12 reverse stock split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":450000,"derivative":{"exercise_price":5,"exercise_date":"2023-02-07","expiration_date":"2024-02-07","underlying":"Common Stock","underlying_shares":450000},"source":{"system":"sec-edgar","filing":"0000899243-23-004412","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924323004412/doc4.xml","form_type":"4"}},{"id":2024387,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-09T21:32:03.000Z","date":"2023-02-07","kind":"purchase","acquired":true,"shares":450000,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of common stock and accompanying warrant were purchased together for $3.98.  The warrants are subject to a 4.99% beneficial ownership limitation on exercise."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amount reflects the effect of the 1-for-12 reverse stock split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4415000,"source":{"system":"sec-edgar","filing":"0000899243-23-004412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924323004412/doc4.xml","form_type":"4"}},{"id":2024386,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2023-02-09T21:32:03.000Z","date":"2023-02-03","kind":"other","acquired":true,"shares":334,"price":3.95,"value":1319.3,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amount reflects the effect of the 1-for-12 reverse stock split."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3965000,"source":{"system":"sec-edgar","filing":"0000899243-23-004412","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924323004412/doc4.xml","form_type":"4"}},{"id":2265015,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":10596027,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"kind","element":"transactionCoding","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":10596027,"derivative":{"exercise_price":0.63,"underlying":"Common Stock","underlying_shares":10596027},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265014,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Pre-Funded Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":10596027,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"kind","element":"transactionCoding","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The Master Fund purchased 10,596,027 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on May 19, 2022.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series E Warrant to purchase one share of common stock of the Issuer (a \"Series E Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $0.63, subject to customary adjustments.  The aggregate purchase price for the 10,596,027 Units was approximately $8.0 million. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series E Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"(Continued from Footnote 5) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":10596027,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":10596027},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265013,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":2072538,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2072538,"derivative":{"exercise_price":0.63,"exercise_date":"2018-12-11","expiration_date":"2025-12-11","underlying":"Common Stock","underlying_shares":2072538},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265012,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":2072538,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.93,"exercise_date":"2018-12-11","expiration_date":"2020-12-11","underlying":"Common Stock","underlying_shares":2072538},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265011,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":2360313,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2360313,"derivative":{"exercise_price":0.63,"exercise_date":"2020-03-13","expiration_date":"2027-09-15","underlying":"Common Stock","underlying_shares":2360313},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265010,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":2360313,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.04,"exercise_date":"2020-03-13","expiration_date":"2025-09-15","underlying":"Common Stock","underlying_shares":2360313},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265009,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":4607692,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 19.99% beneficial owner of the Shares following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4607692,"derivative":{"exercise_price":0.903,"exercise_date":"2020-07-08","expiration_date":"2028-01-08","underlying":"Common Stock","underlying_shares":4607692},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265008,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":4607692,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 19.99% beneficial owner of the Shares following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.903,"exercise_date":"2020-07-08","expiration_date":"2026-01-08","underlying":"Common Stock","underlying_shares":4607692},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265007,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":3175924,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 19.99% beneficial owner of the Shares following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3175924,"derivative":{"exercise_price":0.903,"exercise_date":"2020-07-08","expiration_date":"2028-01-08","underlying":"Common Stock","underlying_shares":3175924},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265006,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Common Stock Purchase Warrants","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":3175924,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 19.99% beneficial owner of the Shares following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":0.903,"exercise_date":"2020-07-08","expiration_date":"2026-01-08","underlying":"Common Stock","underlying_shares":3175924},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265005,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"grant","acquired":true,"shares":4773269,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4773269,"derivative":{"exercise_price":0.63,"exercise_date":"2021-07-08","expiration_date":"2029-01-08","underlying":"Common Stock","underlying_shares":4773269},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2265004,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant (right to buy)","published_at":"2022-05-20T01:24:51.000Z","date":"2022-05-18","kind":"disposition_to_issuer","acquired":false,"shares":4773269,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On May 17, 2022, the Issuer entered into a warrant amendment agreement with the Master Fund, as defined below, pursuant to which the Issuer agreed to amend certain previously issued warrants held by the Master Fund in a transaction that was approved by the Issuer's board of directors pursuant to Rule 16b-3 under the Securities Exchange Act of 1934, as amended."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These warrants are currently exercisable, subject to a blocker provision that prevents the Master Fund from exercising the warrants if it would be more than a 4.99% beneficial owner of the outstanding shares of the Issuer's common stock (collectively, the \"Shares\") following such exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":1.97,"exercise_date":"2021-07-08","expiration_date":"2027-01-08","underlying":"Common Stock","underlying_shares":4773269},"source":{"system":"sec-edgar","filing":"0000899243-22-018968","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924322018968/doc4.xml","form_type":"4"}},{"id":2334989,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-14T21:38:41.000Z","date":"2022-03-14","kind":"purchase","acquired":true,"shares":100000,"price":0.6494,"value":64940.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":47576000,"source":{"system":"sec-edgar","filing":"0000899243-22-010904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322010904/doc4.xml","form_type":"4"}},{"id":2334988,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-14T21:38:41.000Z","date":"2022-03-11","kind":"purchase","acquired":true,"shares":100000,"price":0.6878,"value":68780.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":47476000,"source":{"system":"sec-edgar","filing":"0000899243-22-010904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322010904/doc4.xml","form_type":"4"}},{"id":2334987,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-14T21:38:41.000Z","date":"2022-03-10","kind":"purchase","acquired":true,"shares":26000,"price":0.701,"value":18226.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":47376000,"source":{"system":"sec-edgar","filing":"0000899243-22-010904","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322010904/doc4.xml","form_type":"4"}},{"id":2347212,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-07T23:09:15.000Z","date":"2022-03-07","kind":"purchase","acquired":true,"shares":325000,"price":0.6564,"value":213330.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6298 to $0.6933, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":47350000,"source":{"system":"sec-edgar","filing":"0000899243-22-009744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322009744/doc4.xml","form_type":"4"}},{"id":2347211,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-07T23:09:15.000Z","date":"2022-03-04","kind":"purchase","acquired":true,"shares":135000,"price":0.7045,"value":95107.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7020 to $0.7082, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":47025000,"source":{"system":"sec-edgar","filing":"0000899243-22-009744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322009744/doc4.xml","form_type":"4"}},{"id":2347210,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-03-07T23:09:15.000Z","date":"2022-03-03","kind":"purchase","acquired":true,"shares":50000,"price":0.7139,"value":35695.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46890000,"source":{"system":"sec-edgar","filing":"0000899243-22-009744","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322009744/doc4.xml","form_type":"4"}},{"id":2368414,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-28T22:53:01.000Z","date":"2022-02-25","kind":"purchase","acquired":true,"shares":40000,"price":0.7929,"value":31716.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7877 to $0.7997, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46840000,"source":{"system":"sec-edgar","filing":"0000899243-22-008145","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322008145/doc4.xml","form_type":"4"}},{"id":2368413,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-28T22:53:01.000Z","date":"2022-02-24","kind":"purchase","acquired":true,"shares":100000,"price":0.8009,"value":80090.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7803 to $0.8163, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46800000,"source":{"system":"sec-edgar","filing":"0000899243-22-008145","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322008145/doc4.xml","form_type":"4"}},{"id":2381641,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-22T23:37:32.000Z","date":"2022-02-22","kind":"purchase","acquired":true,"shares":83000,"price":0.772,"value":64076.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7538 to $0.8086, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46700000,"source":{"system":"sec-edgar","filing":"0000899243-22-007249","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322007249/doc4.xml","form_type":"4"}},{"id":2381640,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-22T23:37:32.000Z","date":"2022-02-18","kind":"purchase","acquired":true,"shares":55000,"price":0.8225,"value":45237.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8145 to $0.8293, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46617000,"source":{"system":"sec-edgar","filing":"0000899243-22-007249","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322007249/doc4.xml","form_type":"4"}},{"id":2381639,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-02-22T23:37:32.000Z","date":"2022-02-17","kind":"purchase","acquired":true,"shares":150000,"price":0.815,"value":122250.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8119 to $0.8357, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46562000,"source":{"system":"sec-edgar","filing":"0000899243-22-007249","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322007249/doc4.xml","form_type":"4"}},{"id":2429893,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T23:14:50.000Z","date":"2022-01-20","kind":"purchase","acquired":true,"shares":12000,"price":0.8507,"value":10208.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46412000,"source":{"system":"sec-edgar","filing":"0000899243-22-002693","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322002693/doc4.xml","form_type":"4"}},{"id":2429892,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T23:14:50.000Z","date":"2022-01-19","kind":"purchase","acquired":true,"shares":93700,"price":0.8757,"value":82053.09,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8501 to $0.8956, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46400000,"source":{"system":"sec-edgar","filing":"0000899243-22-002693","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322002693/doc4.xml","form_type":"4"}},{"id":2429891,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-20T23:14:50.000Z","date":"2022-01-18","kind":"purchase","acquired":true,"shares":206300,"price":0.8833,"value":182224.79,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.8762 to $0.9029, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46306300,"source":{"system":"sec-edgar","filing":"0000899243-22-002693","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322002693/doc4.xml","form_type":"4"}},{"id":2434645,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-14T22:49:32.000Z","date":"2022-01-14","kind":"purchase","acquired":true,"shares":85000,"price":0.9291,"value":78973.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9137 to $0.9497, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46100000,"source":{"system":"sec-edgar","filing":"0000899243-22-002025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322002025/doc4.xml","form_type":"4"}},{"id":2434644,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-14T22:49:32.000Z","date":"2022-01-13","kind":"purchase","acquired":true,"shares":312700,"price":1.0042,"value":314013.34,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":46015000,"source":{"system":"sec-edgar","filing":"0000899243-22-002025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322002025/doc4.xml","form_type":"4"}},{"id":2434643,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-14T22:49:32.000Z","date":"2022-01-12","kind":"purchase","acquired":true,"shares":57300,"price":1.0433,"value":59781.09,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.0300 to $1.0550, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":45702300,"source":{"system":"sec-edgar","filing":"0000899243-22-002025","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322002025/doc4.xml","form_type":"4"}},{"id":2437467,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T23:18:29.000Z","date":"2022-01-11","kind":"purchase","acquired":true,"shares":16003,"price":0.9587,"value":15342.0761,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9484 to $0.9795, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":45645000,"source":{"system":"sec-edgar","filing":"0000899243-22-001618","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322001618/doc4.xml","form_type":"4"}},{"id":2437466,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T23:18:29.000Z","date":"2022-01-10","kind":"purchase","acquired":true,"shares":491097,"price":0.9868,"value":484614.5196,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.9733 to $1.0064, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":45628997,"source":{"system":"sec-edgar","filing":"0000899243-22-001618","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322001618/doc4.xml","form_type":"4"}},{"id":2437465,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-01-11T23:18:29.000Z","date":"2022-01-07","kind":"purchase","acquired":true,"shares":137900,"price":1.0368,"value":142974.72,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.0097 to $1.0811, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":45137900,"source":{"system":"sec-edgar","filing":"0000899243-22-001618","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924322001618/doc4.xml","form_type":"4"}},{"id":2565179,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T18:25:07.000Z","date":"2021-09-17","kind":"purchase","acquired":true,"shares":5454545,"price":2.2,"value":11999999.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.) (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":45000000,"source":{"system":"sec-edgar","filing":"0000899243-21-036402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924321036402/doc4.xml","form_type":"4"}},{"id":2565178,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T18:25:07.000Z","date":"2021-09-16","kind":"purchase","acquired":true,"shares":150000,"price":2.2797,"value":341955.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $2.1874 to $2.3089, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.) (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39545455,"source":{"system":"sec-edgar","filing":"0000899243-21-036402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924321036402/doc4.xml","form_type":"4"}},{"id":2565177,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-17T18:25:07.000Z","date":"2021-09-15","kind":"purchase","acquired":true,"shares":95455,"price":2.2623,"value":215947.8465,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $2.1461 to $2.3594, inclusive.  The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Avalo Therapeutics, Inc. (f/k/a Cerecor Inc.) (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39395455,"source":{"system":"sec-edgar","filing":"0000899243-21-036402","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924321036402/doc4.xml","form_type":"4"}},{"id":2597386,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-18T21:54:48.000Z","date":"2021-08-18","kind":"purchase","acquired":true,"shares":20000,"price":2.7775,"value":55550.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39300000,"source":{"system":"sec-edgar","filing":"0000899243-21-033505","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924321033505/doc4.xml","form_type":"4"}},{"id":2597385,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-18T21:54:48.000Z","date":"2021-08-16","kind":"purchase","acquired":true,"shares":30000,"price":2.7546,"value":82638.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $2.7507 to $2.774, inclusive.  The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39280000,"source":{"system":"sec-edgar","filing":"0000899243-21-033505","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000089924321033505/doc4.xml","form_type":"4"}},{"id":2611173,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-06T19:15:57.000Z","date":"2021-08-06","kind":"purchase","acquired":true,"shares":25000,"price":2.8252,"value":70630.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities (the \"Shares\") of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39250000,"source":{"system":"sec-edgar","filing":"0001567619-21-014631","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156761921014631/doc1.xml","form_type":"4"}},{"id":2611172,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-06T19:15:57.000Z","date":"2021-08-05","kind":"purchase","acquired":true,"shares":25000,"price":2.7718,"value":69295.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities (the \"Shares\") of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39225000,"source":{"system":"sec-edgar","filing":"0001567619-21-014631","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156761921014631/doc1.xml","form_type":"4"}},{"id":2611171,"issuer":{"id":4936,"kind":"organization","name":"Avalo Therapeutics, Inc.","symbol":"AVTX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-06T19:15:57.000Z","date":"2021-08-04","kind":"purchase","acquired":true,"shares":100000,"price":2.6859,"value":268590.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.6541 to $2.6997, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (2) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities (the \"Shares\") of Cerecor Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":39200000,"source":{"system":"sec-edgar","filing":"0001567619-21-014631","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1534120/000156761921014631/doc1.xml","form_type":"4"}},{"id":2617060,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T21:09:33.000Z","date":"2021-08-02","kind":"sale","acquired":false,"shares":192775,"price":2.402,"value":463045.55,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $2.3595 to $2.5144, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":785000,"source":{"system":"sec-edgar","filing":"0001567619-21-014361","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000156761921014361/doc1.xml","form_type":"4"}},{"id":2617059,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-03T21:09:33.000Z","date":"2021-07-30","kind":"sale","acquired":false,"shares":68188,"price":2.692,"value":183562.096,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $2.6145\t to $2.7604, inclusive.  The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":977775,"source":{"system":"sec-edgar","filing":"0001567619-21-014361","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000156761921014361/doc1.xml","form_type":"4"}},{"id":2621983,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-27","kind":"exercise","acquired":false,"shares":4092,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The Series C Convertible Preferred Stock has no expiration date and was convertible at any time at the option of the Master Fund."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":4.8,"exercise_date":"2018-04-17","underlying":"Common Stock","underlying_shares":852500},"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621982,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-29","kind":"sale","acquired":false,"shares":400000,"price":3,"value":1200000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $2.85 to $3.24, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1045963,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621981,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-28","kind":"sale","acquired":false,"shares":375443,"price":3.2831,"value":1232616.9133,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $3.1713 to $3.4093, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1445963,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621980,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-27","kind":"sale","acquired":false,"shares":581614,"price":3.799,"value":2209551.586,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $3.5852 to $3.9402, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1821406,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621979,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-27","kind":"sale","acquired":false,"shares":532069,"price":4.5877,"value":2440972.9513,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $4.0011 to $4.9908, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2403020,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621978,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-27","kind":"sale","acquired":false,"shares":729114,"price":5.4397,"value":3966161.4258,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $5.1066 to $5.9464, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2935089,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621977,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-27","kind":"sale","acquired":false,"shares":461797,"price":6.4549,"value":2980853.4553,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $6.0052 to $6.9970, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3664203,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621976,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-27","kind":"sale","acquired":false,"shares":73101,"price":7.0602,"value":516107.6802,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $7.002 to $7.1559, inclusive.  The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7), (8) and (9) to this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4126000,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2621975,"issuer":{"id":7940,"kind":"organization","name":"KIORA PHARMACEUTICALS INC","symbol":"KPRX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-07-29T23:59:52.000Z","date":"2021-07-27","kind":"exercise","acquired":true,"shares":852500,"price":4.8,"value":4092000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of EyeGate Pharmaceuticals, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4199101,"source":{"system":"sec-edgar","filing":"0000899243-21-030722","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1372514/000089924321030722/doc4.xml","form_type":"4"}},{"id":2637597,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-07-09T22:03:22.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":4773269,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4773269,"derivative":{"exercise_price":1.97,"underlying":"Common Stock","underlying_shares":4773269},"source":{"system":"sec-edgar","filing":"0000899243-21-028023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924321028023/doc4.xml","form_type":"4"}},{"id":2637596,"issuer":{"id":979,"kind":"organization","name":"TENAX THERAPEUTICS, INC.","symbol":"TENX"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Warrant (right to buy)","published_at":"2021-07-09T22:03:22.000Z","date":"2021-07-08","kind":"grant","acquired":true,"shares":4773269,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"kind","element":"transactionCoding","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Master Fund purchased 4,773,269 units of the securities of the Issuer directly from the Issuer in a private placement transaction that closed on July 8, 2021.  Each Unit consists of (i) 1 pre-funded warrant to purchase one share of common stock of the Issuer (a \"Pre-Funded Warrant\") for an exercise price of $0.0001, subject to customary adjustments, and (ii) 1 Series A Warrant to purchase one share of common stock of the Issuer (a \"Series A Warrant\", and together with the Pre-Funded Warrants, the \"Warrants\") for an exercise price of $1.97, subject to customary adjustments.  The aggregate purchase price for the 4,773,269 Units was $9,999,998.56 or approximately $2.095 per Unit. The Pre-Funded Warrants were immediately exercisable upon issuance and expire when they are fully exercised.  The Series A Warrants were immediately exercisable upon issuance and expire five and one half years following the date of issuance."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued from footnote 2) The Warrants are subject to a limitation on exercise pursuant to which the Master Fund may not exercise the Warrants if such exercise would result in the Master Fund, together with the Master Fund's affiliates and any person acting as a group together with the Master Fund or any of the Master Fund's affiliates, beneficially owning greater than 9.99% of the number of shares of common stock outstanding immediately after giving effect to the issuance of shares of common stock upon exercise."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"The reported securities of Tenax Therapeutics, Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and collectively with the Master Fund and Armistice Capital, the \"Reporting Persons\"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4773269,"derivative":{"exercise_price":0.0001,"underlying":"Common Stock","underlying_shares":4773269},"source":{"system":"sec-edgar","filing":"0000899243-21-028023","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/34956/000089924321028023/doc4.xml","form_type":"4"}},{"id":2651603,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Fourth Amendment to Credit Agreement, dated January 19, 2021 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by Pre-Merger ReShape with the SEC on January 20, 2021) and the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Fourth Amendment to Credit Agreement, dated January 19, 2021 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by Pre-Merger ReShape with the SEC on January 20, 2021) and the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Fourth Amendment to Credit Agreement, dated January 19, 2021 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by Pre-Merger ReShape with the SEC on January 20, 2021) and the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651602,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":563700,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F9","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Fourth Amendment to Credit Agreement, dated January 19, 2021 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by Pre-Merger ReShape with the SEC on January 20, 2021) and the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Fourth Amendment to Credit Agreement, dated January 19, 2021 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by Pre-Merger ReShape with the SEC on January 20, 2021) and the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F9","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Fourth Amendment to Credit Agreement, dated January 19, 2021 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.3 to the Form 8-K filed by Pre-Merger ReShape with the SEC on January 20, 2021) and the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":563700},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651601,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Third Amendment to Credit Agreement, dated December 16, 2020 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Pre-Merger ReShape with the SEC on December 22, 2020) and the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Third Amendment to Credit Agreement, dated December 16, 2020 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Pre-Merger ReShape with the SEC on December 22, 2020) and the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Third Amendment to Credit Agreement, dated December 16, 2020 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Pre-Merger ReShape with the SEC on December 22, 2020) and the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651600,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":2254800,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Third Amendment to Credit Agreement, dated December 16, 2020 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Pre-Merger ReShape with the SEC on December 22, 2020) and the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Third Amendment to Credit Agreement, dated December 16, 2020 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Pre-Merger ReShape with the SEC on December 22, 2020) and the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The terms of this Warrant are substantially similar to the terms of the Additional Series G Warrants, as modified by the Third Amendment to Credit Agreement, dated December 16, 2020 by and between Pre-Merger ReShape and the Master Fund (incorporated by reference to Exhibit 10.1 to the Form 8-K filed by Pre-Merger ReShape with the SEC on December 22, 2020) and the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":2254800},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651599,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The terms of these Series G Warrants (\"Additional Series G Warrants\") are substantially similar to the Existing Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The terms of these Series G Warrants (\"Additional Series G Warrants\") are substantially similar to the Existing Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The terms of these Series G Warrants (\"Additional Series G Warrants\") are substantially similar to the Existing Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651598,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":676440,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The terms of these Series G Warrants (\"Additional Series G Warrants\") are substantially similar to the Existing Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The terms of these Series G Warrants (\"Additional Series G Warrants\") are substantially similar to the Existing Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The terms of these Series G Warrants (\"Additional Series G Warrants\") are substantially similar to the Existing Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":676440},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651597,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The terms of these Series G Warrants are substantially similar to the New Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The terms of these Series G Warrants are substantially similar to the New Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The terms of these Series G Warrants are substantially similar to the New Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651596,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":676440,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"The terms of these Series G Warrants are substantially similar to the New Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The terms of these Series G Warrants are substantially similar to the New Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The terms of these Series G Warrants are substantially similar to the New Series G Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":676440},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651595,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The terms of these Series E Warrants are substantially similar to the Series E Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The terms of these Series E Warrants are substantially similar to the Series E Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The terms of these Series E Warrants are substantially similar to the Series E Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651594,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":1479713,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The terms of these Series E Warrants are substantially similar to the Series E Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The terms of these Series E Warrants are substantially similar to the Series E Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The terms of these Series E Warrants are substantially similar to the Series E Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to Pre-Merger ReShape, as modified by the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":1479713},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651593,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The terms of these Series A Warrants are substantially similar to the Series A Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to ReShape Weightloss Inc. (then-named Reshape Lifesciences Inc.) (\"Pre-Merger ReShape\"), as modified by the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Optimus Merger Sub, Inc., and Pre-Merger ReShape (incorporated by reference to Exhibit 2.1 the Form 8-K filed by Pre-Merger ReShape with the SEC on June 15, 2021) (the \"Merger Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The terms of these Series A Warrants are substantially similar to the Series A Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to ReShape Weightloss Inc. (then-named Reshape Lifesciences Inc.) (\"Pre-Merger ReShape\"), as modified by the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Optimus Merger Sub, Inc., and Pre-Merger ReShape (incorporated by reference to Exhibit 2.1 the Form 8-K filed by Pre-Merger ReShape with the SEC on June 15, 2021) (the \"Merger Agreement\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The terms of these Series A Warrants are substantially similar to the Series A Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to ReShape Weightloss Inc. (then-named Reshape Lifesciences Inc.) (\"Pre-Merger ReShape\"), as modified by the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Optimus Merger Sub, Inc., and Pre-Merger ReShape (incorporated by reference to Exhibit 2.1 the Form 8-K filed by Pre-Merger ReShape with the SEC on June 15, 2021) (the \"Merger Agreement\")."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651592,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Warrants","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":false,"shares":1479713,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"The terms of these Series A Warrants are substantially similar to the Series A Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to ReShape Weightloss Inc. (then-named Reshape Lifesciences Inc.) (\"Pre-Merger ReShape\"), as modified by the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Optimus Merger Sub, Inc., and Pre-Merger ReShape (incorporated by reference to Exhibit 2.1 the Form 8-K filed by Pre-Merger ReShape with the SEC on June 15, 2021) (the \"Merger Agreement\")."},{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The terms of these Series A Warrants are substantially similar to the Series A Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to ReShape Weightloss Inc. (then-named Reshape Lifesciences Inc.) (\"Pre-Merger ReShape\"), as modified by the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Optimus Merger Sub, Inc., and Pre-Merger ReShape (incorporated by reference to Exhibit 2.1 the Form 8-K filed by Pre-Merger ReShape with the SEC on June 15, 2021) (the \"Merger Agreement\")."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The terms of these Series A Warrants are substantially similar to the Series A Warrants previously listed on the Reporting Persons' Form 4 dated September 16, 2020 with respect to ReShape Weightloss Inc. (then-named Reshape Lifesciences Inc.) (\"Pre-Merger ReShape\"), as modified by the Agreement and Plan of Merger, dated as of January 19, 2021, by and among the Issuer, Optimus Merger Sub, Inc., and Pre-Merger ReShape (incorporated by reference to Exhibit 2.1 the Form 8-K filed by Pre-Merger ReShape with the SEC on June 15, 2021) (the \"Merger Agreement\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"underlying":"COMMON STOCK","underlying_shares":1479713},"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651591,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."}],"balance_after":7223346,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651590,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":563700,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":7223346,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651589,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."}],"balance_after":6659646,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651588,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":2254800,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":6659646,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651587,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."}],"balance_after":4404846,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651586,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":676440,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":4404846,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651585,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."}],"balance_after":3728406,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651584,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":676440,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3728406,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651583,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."}],"balance_after":3051966,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651582,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":1479713,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":3051966,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651581,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."}],"balance_after":1572253,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2651580,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-30T01:44:48.000Z","date":"2021-06-28","kind":"other","acquired":true,"shares":1479713,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"kind","element":"transactionCoding","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"On June 28, 2021, the Issuer and the Master Fund entered into an agreement regarding an Inducement Offer to Exercise Common Stock Purchase Warrants (the \"Inducement Agreement\"). The Inducement Agreement provided, inter alia, that the Master Fund would exercise the warrants in the transactions reported herein (the \"Existing Warrants\") in exchange for an aggregate price of $41,179,303.17. In consideration for exercising in full all of the Existing Warrants held by the Master Fund (the \"Warrant Exercise\"), at an exercise price equal the sum of (a) $0.09375 per Share underlying the New Warrants (as defined below) issued to the Master Fund plus (b) the lower of (i) the current exercise price set forth in the Existing Warrants, and (ii) $6.00 per warrant share, the Issuer will issue the Master Fund or its designee a new unregistered Common Stock Purchase Warrants (\"New Warrants\")"},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"[continued from Footnote 2] to purchase 5,348,105 Shares, which New Warrant shall be substantially in the form of the Existing Warrants (except that the New Warrants will include a beneficial ownership limitation of 9.99% (\"Beneficial Ownership Limitation\")), are exercisable immediately with an expiration date on June 28, 2026, and an exercise price equal to $6.00. The Shares to be received resulting from the Warrant Exercise are subject to the Beneficial Ownership Limitation and are held in abeyance until they are able to be received in accordance with the terms of the Inducement Agreement (and thus the Reporting Persons do not beneficially own Shares in abeyance).  The foregoing descriptions of each of the Inducement Agreement and the New Warrants are qualified in their entirety by the terms and conditions of the Inducement Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1572253,"source":{"system":"sec-edgar","filing":"0000919574-21-004321","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004321/ownership.xml","form_type":"4"}},{"id":2658681,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T12:58:05.000Z","date":"2021-06-18","kind":"sale","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F8","text":"Additionally, the Reporting Persons no longer have beneficial ownership of 13,333 Shares as a result of the settlement of a transaction made prior to the reporting period. Accordingly, the Reporting Persons have beneficial ownership of 92,540 Shares."}],"balance_after":105873,"source":{"system":"sec-edgar","filing":"0000919574-21-004191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004191/ownership.xml","form_type":"4"}},{"id":2658680,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T12:58:05.000Z","date":"2021-06-18","kind":"sale","acquired":false,"shares":685583,"price":5.48,"value":3756994.84,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"This constitutes the weighted average purchase price. The prices range from $5.30 to $5.86. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":105873,"source":{"system":"sec-edgar","filing":"0000919574-21-004191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004191/ownership.xml","form_type":"4"}},{"id":2658679,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T12:58:05.000Z","date":"2021-06-17","kind":"sale","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"balance_after":791456,"source":{"system":"sec-edgar","filing":"0000919574-21-004191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004191/ownership.xml","form_type":"4"}},{"id":2658678,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T12:58:05.000Z","date":"2021-06-17","kind":"sale","acquired":false,"shares":81366,"price":7.13,"value":580139.58,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"This constitutes the weighted average purchase price. The prices range from $6.91 to $7.51. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":791456,"source":{"system":"sec-edgar","filing":"0000919574-21-004191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004191/ownership.xml","form_type":"4"}},{"id":2658677,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T12:58:05.000Z","date":"2021-06-17","kind":"sale","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"balance_after":872822,"source":{"system":"sec-edgar","filing":"0000919574-21-004191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004191/ownership.xml","form_type":"4"}},{"id":2658676,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T12:58:05.000Z","date":"2021-06-17","kind":"sale","acquired":false,"shares":1024844,"price":6.2,"value":6354032.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"This constitutes the weighted average purchase price. The prices range from $5.86 to $6.84. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":872822,"source":{"system":"sec-edgar","filing":"0000919574-21-004191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004191/ownership.xml","form_type":"4"}},{"id":2658675,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T12:58:05.000Z","date":"2021-06-16","kind":"sale","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"balance_after":1897666,"source":{"system":"sec-edgar","filing":"0000919574-21-004191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004191/ownership.xml","form_type":"4"}},{"id":2658674,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T12:58:05.000Z","date":"2021-06-16","kind":"sale","acquired":false,"shares":50040,"price":8.52,"value":426340.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This constitutes the weighted average purchase price. The prices range from $8.46 to $8.54. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1897666,"source":{"system":"sec-edgar","filing":"0000919574-21-004191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004191/ownership.xml","form_type":"4"}},{"id":2658673,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T12:58:05.000Z","date":"2021-06-16","kind":"sale","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"balance_after":1947706,"source":{"system":"sec-edgar","filing":"0000919574-21-004191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004191/ownership.xml","form_type":"4"}},{"id":2658672,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T12:58:05.000Z","date":"2021-06-16","kind":"sale","acquired":false,"shares":73591,"price":7.92,"value":582840.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This constitutes the weighted average purchase price. The prices range from $7.30 to $8.06. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":1947706,"source":{"system":"sec-edgar","filing":"0000919574-21-004191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004191/ownership.xml","form_type":"4"}},{"id":2658671,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T12:58:05.000Z","date":"2021-06-16","kind":"sale","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote 1"},"balance_after":2021297,"source":{"system":"sec-edgar","filing":"0000919574-21-004191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004191/ownership.xml","form_type":"4"}},{"id":2658670,"issuer":{"id":1824,"kind":"organization","name":"Vyome Holdings, Inc","symbol":"HIND"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":2,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-22T12:58:05.000Z","date":"2021-06-16","kind":"sale","acquired":false,"shares":388045,"price":6.52,"value":2530053.4,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This constitutes the weighted average purchase price. The prices range from $5.96 to $6.86. The Reporting Persons will provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of Shares purchased at each separate price."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"The reported securities (the \"Shares\") of ReShape Lifesciences Inc. (the \"Issuer\") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the \"Master Fund\"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital (\"Mr. Boyd\", and together with Armistice Capital, the \"Reporting Persons\"). Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":2021297,"source":{"system":"sec-edgar","filing":"0000919574-21-004191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1427570/000091957421004191/ownership.xml","form_type":"4"}},{"id":2658494,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2026-01-19","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658493,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":1000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2026-01-19","underlying":"Common Stock","underlying_shares":1000000},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658492,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658491,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Warrant","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":4000000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.5,"expiration_date":"2025-12-16","underlying":"Common Stock","underlying_shares":4000000},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658490,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Warrants","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":0,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.7,"expiration_date":"2025-03-25","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}},{"id":2658489,"issuer":{"id":137993,"kind":"organization","name":"ReShape Weightloss Inc.","symbol":"RSLS"},"owners":[{"id":97018,"kind":"organization","name":"ARMISTICE CAPITAL, LLC","position":1,"cik":"0001601086","reported_name":"ARMISTICE CAPITAL, LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":106092,"kind":"organization","name":"Armistice Capital Master Fund Ltd.","position":2,"cik":"0001633584","reported_name":"Armistice Capital Master Fund Ltd.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":111829,"kind":"person","name":"Boyd Steven","position":3,"cik":"0001706140","reported_name":"Boyd Steven","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series G Warrants","published_at":"2021-06-22T08:33:40.000Z","date":"2021-06-15","kind":"other","acquired":false,"shares":1200000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These warrants are currently exercisable and became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"These warrants became warrants to purchase shares of Combined Company's common stock as of the effective date of the Merger pursuant to the conversion ratio and all other terms of the Merger Agreement."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities were directly held by the Master Fund. The reported securities may have been deemed to be indirectly beneficially owned by Armistice Capital, LLC (\"Armistice Capital\"), as the investment manager of the Master Fund. The reported securities may also have been deemed to be indirectly beneficially owned by Steven Boyd as Managing Member of Armistice Capital. Armistice Capital and Mr. Boyd disclaim beneficial ownership of the disposed securities except to the extent of their respective former pecuniary interests therein, and this report shall not be deemed an admission that either of them were the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose."}],"balance_after":0,"derivative":{"exercise_price":3.7,"expiration_date":"2025-03-25","underlying":"Common Stock","underlying_shares":1200000},"source":{"system":"sec-edgar","filing":"0000919574-21-004187","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1371217/000091957421004187/ownership.xml","form_type":"4"}}],"next_cursor":"2021-06-22T08:33:40.000000Z,2658489"}